Tonix Pharmaceuticals Holding Corp.
TNXP
$12.87
-$0.29-2.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.54M | 6.88M | 5.39M | 3.29M | 2.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.54M | 6.88M | 5.39M | 3.29M | 2.00M |
| Cost of Revenue | 703.00K | 1.58M | 1.06M | 1.37M | 3.27M |
| Gross Profit | 12.84M | 5.30M | 4.33M | 1.92M | -1.27M |
| SG&A Expenses | 35.96M | 28.62M | 35.68M | 25.70M | 16.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.08M | 48.42M | 53.68M | 36.36M | 30.29M |
| Operating Income | -42.54M | -41.54M | -48.29M | -33.07M | -28.30M |
| Income Before Tax | -40.55M | -40.19M | -46.91M | -32.01M | -28.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.55M | -40.19M | -46.91M | -32.01M | -28.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.55M | -40.19M | -46.91M | -32.01M | -28.27M |
| EBIT | -42.54M | -41.54M | -48.29M | -33.07M | -28.30M |
| EBITDA | -41.92M | -40.98M | -47.80M | -32.61M | -27.81M |
| EPS Basic | -2.44 | -2.93 | -3.98 | -3.59 | -3.86 |
| Normalized Basic EPS | -1.52 | -1.83 | -2.48 | -2.24 | -2.41 |
| EPS Diluted | -2.44 | -2.93 | -3.98 | -3.59 | -3.86 |
| Normalized Diluted EPS | -1.52 | -1.83 | -2.48 | -2.24 | -2.41 |
| Average Basic Shares Outstanding | 16.64M | 13.71M | 11.80M | 8.92M | 7.33M |
| Average Diluted Shares Outstanding | 16.64M | 13.71M | 11.80M | 8.92M | 7.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |